Full Text Journal Articles by
Author Jean Hoffman Censits

Advertisement

Find full text journal articles






New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?

Jean Hoffman-Censits, Kara Lombardo, David McConkey, Noah M Hahn, Babar Bashir, Wm Kevin Kelly, Burles Johnson, Andres Matoso,

Enfortumab vedotin (EV) was FDA approved in December 2019 for platinum- and checkpoint-refractory urothelial cancer based on an exceptional 44% response rate, and is currently approved for use after platinum and checkpoint inhibitor therapy. Enfortumab is an antibody-drug conjugate that targets Nectin-4, which is widely expressed in urothelial cancer. Despite ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Molecular subtypes of upper tract urothelial cancer: Setting the stage for precision therapy.

David J McConkey, Nirmish Singla, Phillip Pierorazio, Kara Lombardo, Andres Matoso, Jean Hoffman-Censits,

A comprehensive genomic characterization of a large, high-quality cohort of upper tract urothelial carcinomas (UTUCs) in this issue of Cancer Cell reveals that UTUCs can be divided into five DNA-based molecular subtypes. Feasibility data establish that molecular subtyping can be performed non-invasively by sequencing tumor DNA in urine. ... Read more >>

Cancer Cell (Cancer cell)
[2021, 39(6):745-747]

Cited: 0 times

View full text PDF listing >>



Advertisement

Imaging urothelial bladder cancer: A VPAC PET targeted approach.

Mathew L Thakur, Sushil K Tripathi, Leonard G Gomella, Ebru Salmanoglu, Sung Kim, William K Kelly, Scott W Keith, Charles Intenzo, Peter McCue, Jean Hoffman-Censits, Edouard J Trabulsi,

INTRODUCTION Accurate staging of urothelial bladder cancer (UBC) with imaging, which guides effective bladder cancer treatment, remains challenging. This investigation is to validate a hypothesis that targeting Vasoactive intestinal and pituitary adenylate cyclase activating peptide (VPAC) receptors using ⁶⁴Cu-TP3805 can PET image UBC efficiently.<h4>Materials and methods</h4>Nineteen patients (44-84 years of ... Read more >>

Can J Urol (The Canadian journal of urology)
[2021, 28(2):10596-10602]

Cited: 0 times

View full text PDF listing >>



Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes.

Jean H Hoffman-Censits, Kara A Lombardo, Vamsi Parimi, Sonia Kamanda, Woonyoung Choi, Noah M Hahn, David J McConkey, Bridget M McGuire, Trinity J Bivalacqua, Max Kates, Andres Matoso,

The antibody-drug conjugate enfortumab-vedotin acts by targeting nectin-4, a protein that is nearly ubiquitously expressed in conventional urothelial cancer. However, expression of nectin-4 in morphologic variants of urothelial carcinoma and nonurothelial histotypes was unknown. Immunohistochemistry for nectin-4 using was performed on 169 patients including 83 with nonmuscle invasive bladder cancer ... Read more >>

Appl Immunohistochem Mol Morphol (Applied immunohistochemistry & molecular morphology : AIMM)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.

Joaquim Bellmunt, Maha Hussain, Jürgen E Gschwend, Peter Albers, Stephane Oudard, Daniel Castellano, Siamak Daneshmand, Hiroyuki Nishiyama, Martin Majchrowicz, Viraj Degaonkar, Yi Shi, Sanjeev Mariathasan, Petros Grivas, Alexandra Drakaki, Peter H O'Donnell, Jonathan E Rosenberg, Daniel M Geynisman, Daniel P Petrylak, Jean Hoffman-Censits, Jens Bedke, Arash Rezazadeh Kalebasty, Yousef Zakharia, Michiel S van der Heijden, Cora N Sternberg, Nicole N Davarpanah, Thomas Powles, ,

<h4>Background</h4>Despite standard curative-intent treatment with neoadjuvant cisplatin-based chemotherapy, followed by radical surgery in eligible patients, muscle-invasive urothelial carcinoma has a high recurrence rate and no level 1 evidence for adjuvant therapy. We aimed to evaluate atezolizumab as adjuvant therapy in patients with high-risk muscle-invasive urothelial carcinoma.<h4>Method</h4>In the IMvigor010 study, a ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2021, 22(4):525-537]

Cited: 3 times

View full text PDF listing >>



Urothelial Carcinoma In Situ of the Bladder: Correlation of CK20 Expression With Adaptive Immune Resistance, Response to BCG Therapy, and Clinical Outcome.

Kara A Lombardo, Belkiss Murati Amador, Vamsi Parimi, Jean Hoffman-Censits, Woonyoung Choi, Noah M Hahn, Max Kates, Trinity J Bivalacqua, David McConkey, Mohammad O Hoque, Andres Matoso,

Immunohistochemical stains have been suggested to aid in diagnostically challenging cases of urothelial carcinoma in-situ (CIS). Although full thickness immunostaining for CK20 is supportive of CIS, a subset of CIS cases is CK20(-), the clinical significance of which was unknown. This study included 43 patients with primary diagnosis of bladder ... Read more >>

Appl Immunohistochem Mol Morphol (Applied immunohistochemistry & molecular morphology : AIMM)
[2021, 29(2):127-135]

Cited: 0 times

View full text PDF listing >>



Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma.

Jens Bedke, Axel S Merseburger, Yohann Loriot, Daniel Castellano, Ernest Choy, Ignacio Duran, Jonathan E Rosenberg, Daniel P Petrylak, Robert Dreicer, Jose L Perez-Gracia, Jean H Hoffman-Censits, Michiel S Van Der Heijden, Julie Pavlova, Lars Thiebach, Sabine de Ducla, Simon Fear, Thomas Powles, Cora N Sternberg,

<h4>Background</h4>The value of a complete response to immune checkpoint inhibitor treatment for urothelial cancer is well recognised, but less is known about long-term outcomes in patients with a partial response or the benefit of achieving disease stabilisation.<h4>Objective</h4>To determine clinical outcomes in patients with a partial response or stable disease on ... Read more >>

Eur Urol Focus (European urology focus)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer.

Judit Börcsök, Zsofia Sztupinszki, Raie Bekele, Sizhi P Gao, Miklos Diossy, Amruta S Samant, Kasia M Dillon, Viktoria Tisza, Sándor Spisák, Orsolya Rusz, Istvan Csabai, Helle Pappot, Zoë J Frazier, David J Konieczkowski, David Liu, Naresh Vasani, James A Rodrigues, David B Solit, Jean H Hoffman-Censits, Elizabeth R Plimack, Jonathan E Rosenberg, Jean-Bernard Lazaro, Mary-Ellen Taplin, Gopa Iyer, Søren Brunak, Rita Lozsa, Eliezer M Van Allen, Dávid Szüts, Kent W Mouw, Zoltan Szallasi,

<h4>Purpose</h4>Cisplatin-based chemotherapy is a first-line treatment for muscle-invasive and metastatic urothelial cancer. Approximately 10% of bladder urothelial tumors have a somatic missense mutation in the nucleotide excision repair (NER) gene, <i>ERCC2</i>, which confers increased sensitivity to cisplatin-based chemotherapy. However, a significant subset of patients is ineligible to receive cisplatin-based therapy ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, 27(7):2011-2022]

Cited: 1 time

View full text PDF listing >>



Site of metastatic recurrence impacts prognosis in patients with high-grade upper tract urothelial carcinoma.

Joseph G Cheaib, Lauren E Claus, Hiten D Patel, Max R Kates, Andres Matoso, Noah M Hahn, Trinity J Bivalacqua, Jean H Hoffman-Censits, Phillip M Pierorazio,

<h4>Purpose</h4>Metastatic recurrence occurs in over 25% of upper tract urothelial carcinoma patients treated with radical nephroureterectomy. While metastatic recurrence suggests poor prognosis, the impact of the specific site of recurrence on prognosis is not well documented.<h4>Materials and methods</h4>We retrospectively analyzed 188 patients who underwent radical nephroureterectomy for high-grade, node-negative upper ... Read more >>

Urol Oncol (Urologic oncology)
[2021, 39(1):74.e9-74.e16]

Cited: 0 times

View full text PDF listing >>



Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience.

Jean Hoffman-Censits, Woonyoung Choi, Trinity J Bivalacqua, Philip Pierorazio, Max Kates, Kara Lombardo, Vamsi Parini, David McConkey, Edouard J Trabulsi, Noah Hahn, Andres Matoso,

Clin Genitourin Cancer (Clinical genitourinary cancer)
[2021, 19(2):176-181]

Cited: 0 times

View full text PDF listing >>



Understanding Psychosocial and Sexual Health Concerns Among Women With Bladder Cancer Undergoing Radical Cystectomy.

Natasha Gupta, Sarah E Van Pilsum Rasmussen, Nora Haney, Armine Smith, Phillip M Pierorazio, Michael H Johnson, Jean Hoffman-Censits, Trinity J Bivalacqua,

<h4>Objective</h4>To better understand the physical and psychosocial components of female sexual dysfunction (FSD) among women undergoing radical cystectomy (RC) for bladder cancer (BCa).<h4>Methods</h4>We conducted semistructured individual interviews and a focus group with pre- and post-RC female patients and their partners regarding the impact of RC on sexual health and psychosocial ... Read more >>

Urology (Urology)
[2021, 151:145-153]

Cited: 0 times

View full text PDF listing >>



Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma.

Yung Lyou, Petros Grivas, Jonathan E Rosenberg, Jean Hoffman-Censits, David I Quinn, Daniel P Petrylak, Matthew Galsky, Ulka Vaishampayan, Ugo De Giorgi, Sumati Gupta, Howard Burris, Jessica Rearden, Ai Li, Hao Wang, Maribel Reyes, Susan Moran, Siamak Daneshmand, Dean Bajorin, Sumanta K Pal,

<h4>Background</h4>Infigratinib (BGJ398) is a potent, selective fibroblast growth factor receptor (FGFR) 1-3 inhibitor with significant activity in metastatic urothelial carcinoma (mUC) bearing FGFR3 alterations. It can cause hyperphosphatemia due to the "on-target" class effect of FGFR1 inhibition.<h4>Objective</h4>To investigate the relationship between hyperphosphatemia and treatment response in patients with mUC.<h4>Intervention</h4>Oral infigratinib ... Read more >>

Eur Urol (European urology)
[2020, 78(6):916-924]

Cited: 0 times

View full text PDF listing >>



Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.

Russell E N Becker, Alexa R Meyer, Aaron Brant, Adam C Reese, Michael J Biles, Kelly T Harris, George Netto, Andres Matoso, Jean Hoffman-Censits, Noah M Hahn, Woonyoung Choi, David McConkey, Phillip M Pierorazio, Michael H Johnson, Mark P Schoenberg, Max R Kates, Alex Baras, Trinity J Bivalacqua,

<h4>Background</h4>Standard of care for patients with muscle-invasive bladder cancer (MIBC) includes neoadjuvant cisplatin-based chemotherapy (NAC) followed by consolidative therapy with either chemoradiation or radical cystectomy (RC). Some patients experience robust pathologic responses to NAC, and these have been reported to associate with somatic mutations in specific gene pathways including DNA ... Read more >>

Eur Urol (European urology)
[2021, 79(3):364-371]

Cited: 0 times

View full text PDF listing >>



Development and evaluation of a bladder Cancer specific survivorship care plan by patients and clinical care providers: a multi-methods approach.

Cheryl T Lee, Nihal E Mohamed, Sailaja Pisipati, Qainat N Shah, Piyush K Agarwal, Tracy M Downs, Michael Droller, Scott M Gilbert, Heather H Goltz, Simon J Hall, Mohamed Hendawi, Jean Hoffman-Censits, Michael O'Donnell, Matthew Kaag, Lawrence I Karsh, Wassim Kassouf, Diane Z Quale, Arthur Sagalowsky, Gary D Steinberg, David M Latini,

<h4>Background, context and purpose</h4>In spite of the mixed evidence for their impact, survivorship Care Plans (SCPs) are recommended to enhance quality of care for cancer survivors. Data on the feasibility of SCPs in bladder cancer (BC) is sparse. Using a mixed-methods approach, this study describes the iterative development, acceptability and ... Read more >>

BMC Health Serv Res (BMC health services research)
[2020, 20(1):686]

Cited: 0 times

View full text PDF listing >>



Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma.

Jean Hoffman-Censits, Sumanta Pal, Constanze Kaiser, Beiying Ding, Joaquim Bellmunt,

<h4>Background</h4>Atezolizumab is a treatment for locally advanced/metastatic urothelial carcinoma (mUC). However, its use in patients with renal insufficiency or UC with mixed variant histology (MVH) is not well characterized.<h4>Objective</h4>To report efficacy and safety of atezolizumab in these special subpopulations from an expanded access program (EAP).<h4>Design, setting, and participants</h4>A total of ... Read more >>

J Immunother Cancer (Journal for immunotherapy of cancer)
[2020, 8(2):]

Cited: 1 time

View full text PDF listing >>



Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

Thomas W Flaig, Philippe E Spiess, Neeraj Agarwal, Rick Bangs, Stephen A Boorjian, Mark K Buyyounouski, Sam Chang, Tracy M Downs, Jason A Efstathiou, Terence Friedlander, Richard E Greenberg, Khurshid A Guru, Thomas Guzzo, Harry W Herr, Jean Hoffman-Censits, Christopher Hoimes, Brant A Inman, Masahito Jimbo, A Karim Kader, Subodh M Lele, Jeff Michalski, Jeffrey S Montgomery, Lakshminarayanan Nandagopal, Lance C Pagliaro, Sumanta K Pal, Anthony Patterson, Elizabeth R Plimack, Kamal S Pohar, Mark A Preston, Wade J Sexton, Arlene O Siefker-Radtke, Jonathan Tward, Jonathan L Wright, Lisa A Gurski, Alyse Johnson-Chilla,

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder cancer, treatment of non-muscle-invasive urothelial bladder cancer, and treatment of metastatic urothelial bladder cancer because important updates have recently been made to these sections. Some ... Read more >>

J Natl Compr Canc Netw (Journal of the National Comprehensive Cancer Network : JNCCN)
[2020, 18(3):329-354]

Cited: 34 times

View full text PDF listing >>



Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.

Sumanta K Pal, Dean Bajorin, Nazli Dizman, Jean Hoffman-Censits, David I Quinn, Daniel P Petrylak, Matthew D Galsky, Ulka Vaishampayan, Ugo De Giorgi, Sumati Gupta, Howard A Burris, Harris S Soifer, Gary Li, Hao Wang, Carl L Dambkowski, Susan Moran, Siamak Daneshmand, Jonathan E Rosenberg,

<h4>Background</h4>Infigratinib (BGJ398) is a potent and selective fibroblast grown factor receptor 1 to 3 (FGFR1-3) inhibitor with significant activity in patients with advanced or metastatic urothelial carcinoma bearing FGFR3 alterations. Given the distinct biologic characteristics of upper tract urothelial carcinoma (UTUC) and urothelial carcinoma of the bladder (UCB), the authors ... Read more >>

Cancer (Cancer)
[2020, 126(11):2597-2606]

Cited: 8 times

View full text PDF listing >>



Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile.

Jean Hoffman-Censits, Woonyoung Choi, Sumanta Pal, Edouard Trabulsi, William Kevin Kelly, Noah M Hahn, David McConkey, Eva Comperat, Andres Matoso, Oliver Cussenot, Geraldine Cancel-Tassin, Megan Hoi Yan Fong, Jeffrey Ross, Russell Madison, Siraj Ali,

Although predominantly urothelial, some bladder cancer and upper tract urothelial cancer (BC/UTUC) harbor histologic variants. Small cell BC (SCBC) variants comprised ˜5% of The Cancer Genome Atlas BC cohort, with a poor prognosis. We describe genomic profiles of BC/UTUC with small cell/neuroendocrine features identified in the Foundation Medicine database from ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, 4(2):297-300]

Cited: 0 times

View full text PDF listing >>



Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer.

Jianqing Lin, Robert B Den, Jacob Greenspan, Timothy N Showalter, Jean H Hoffman-Censits, Costas D Lallas, Edouard J Trabulsi, Leonard G Gomella, Mark D Hurwitz, Benjamin Leiby, Adam P Dicker, W Kevin Kelly,

<h4>Purpose</h4>Cabazitaxel has been demonstrated to improve the overall survival for men with metastatic castrate-resistant prostate cancer. The purpose of this study was to determine the maximum tolerated dose for concurrent cabazitaxel with androgen deprivation and intensity modulated radiation therapy in men with high-risk prostate cancer.<h4>Methods and materials</h4>Twenty men were enrolled ... Read more >>

Int J Radiat Oncol Biol Phys (International journal of radiation oncology, biology, physics)
[2020, 106(5):939-947]

Cited: 0 times

View full text PDF listing >>



Reply by Authors.

Vitaly Margulis, Maneka Puligandla, Edouard J Trabulsi, Elizabeth R Plimack, Elizabeth R Kessler, Surena F Matin, Guilherme Godoy, Ajjai Alva, Noah M Hahn, Michael A Carducci, Jean Hoffman-Censits, ,

J Urol (The Journal of urology)
[2020, 203(4):697-698]

Cited: 0 times

View full text PDF listing >>



Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.

Benjamin Miron, Jean H Hoffman-Censits, Fern Anari, John O'Neill, Daniel M Geynisman, Matthew R Zibelman, Alexander Kutikov, Rosalia Viterbo, Richard E Greenberg, David Chen, Costas D Lallas, Edouard J Trabulsi, R Katherine Alpaugh, Essel Dulaimi, Erica A Golemis, Robert Uzzo, Eric A Ross, Elizabeth R Plimack,

Cisplatin-based neoadjuvant chemotherapy (NAC) has demonstrated an overall survival (OS) benefit in muscle-invasive bladder cancer (MIBC). However, only a subset of patients (25-50%) have a pathologic complete response at cystectomy. Using a cohort of 58 patients from two phase 2 trials, our group previously reported that mutations in the ATM, ... Read more >>

Eur Urol Oncol (European urology oncology)
[2020, 3(4):544-547]

Cited: 5 times

View full text PDF listing >>



A Pilot Study of Radiation Therapy in Combination With Pembrolizumab in Patients With Metastatic Renal Cell Cancer.

Jianqing Lin, Andrew J Song, Jean Hoffman-Censits, Benjamin E Leiby, Madalina Tuluc, Colette Shaw, Larry Harshyne, Rhonda Kean, Voichita Bar-Ad, Robert B Den, Mark D Hurwitz, Jennifer Louie, Sherin Philipose, Sandeep P Deshmukh, Jennifer M Johnson, Adam P Dicker, Douglas C Hooper, William K Kelly, Bo Lu,

<h4>Objectives</h4>There is no study published regarding the benefit of radiation therapy (RT) in combination with immune checkpoint inhibitors (ICIs) for the treatment of metastatic renal cell cancer (mRCC). This report is part of an exploratory study aiming to determine the immunomodulatory activity of RT alone or in combination with pembrolizumab ... Read more >>

Am J Clin Oncol (American journal of clinical oncology)
[2020, 43(2):82-86]

Cited: 1 time

View full text PDF listing >>



Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma.

Vitaly Margulis, Maneka Puligandla, Edouard J Trabulsi, Elizabeth R Plimack, Elizabeth R Kessler, Surena F Matin, Guilherme Godoy, Ajjai Alva, Noah M Hahn, Michael A Carducci, Jean Hoffman-Censits, ,

<h4>Purpose</h4>Data supporting neoadjuvant chemotherapy of high grade upper tract urothelial carcinoma are scant. In this multi-institution, prospective, phase II trial we investigated pathological complete responses after neoadjuvant chemotherapy of high grade upper tract urothelial carcinoma.<h4>Materials and methods</h4>Patients with high grade upper tract urothelial carcinoma in whom nephroureterectomy was planned were ... Read more >>

J Urol (The Journal of urology)
[2020, 203(4):690-698]

Cited: 5 times

View full text PDF listing >>



Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

Sumanta K Pal, Jonathan E Rosenberg, Jean H Hoffman-Censits, Raanan Berger, David I Quinn, Matthew D Galsky, Juergen Wolf, Christian Dittrich, Bhumsuk Keam, Jean-Pierre Delord, Jan H M Schellens, Gwenaelle Gravis, Jacques Medioni, Pablo Maroto, Virote Sriuranpong, Chaiyut Charoentum, Howard A Burris, Viktor Grünwald, Daniel Petrylak, Ulka Vaishampayan, Eliahu Gez, Ugo De Giorgi, Jae-Lyun Lee, Jens Voortman, Sumati Gupta, Sunil Sharma, Amir Mortazavi, David J Vaughn, Randi Isaacs, Katie Parker, Xueying Chen, Kun Yu, Dale Porter, Diana Graus Porta, Dean F Bajorin,

BGJ398, a potent and selective pan-FGFR antagonist, was prospectively evaluated in patients with metastatic urothelial carcinoma bearing a diverse array of FGFR3 alterations. Patients (N = 67) who were unable to receive platinum chemotherapy were enrolled. The majority (70.1%) had received two or more prior antineoplastic therapies. BGJ398 was administered ... Read more >>

Cancer Discov (Cancer discovery)
[2018, 8(7):812-821]

Cited: 50 times

View full text PDF listing >>



Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).

Jonathan E Rosenberg, Noah M Hahn, Meredith M Regan, Lillian Werner, Ajjai Alva, Saby George, Joel Picus, Robert Alter, Arjun Balar, Jean Hoffman-Censits, Petros Grivas, Richard Lauer, Elizabeth A Guancial, Christopher Hoimes, Guru Sonpavde, Constantine Albany, Mark N Stein, Tim Breen, Cindy Jacobs, Kirsten Anderson, Joaquim Bellmunt, Aly-Khan A Lalani, Sumanta Pal, Toni K Choueiri,

<h4>Background</h4>A randomised study to assess the addition of apatorsen, an antisense oligonucleotide that inhibits Hsp27 expression, to docetaxel in patients with metastatic urothelial carcinoma (mUC) relapsed after prior platinum-based chemotherapy.<h4>Methods</h4>Multicentre, phase II study with 1:1 randomisation to apatorsen (three loading doses at 600 mg intravenous followed by weekly doses) plus docetaxel ... Read more >>

Br J Cancer (British journal of cancer)
[2018, 118(11):1434-1441]

Cited: 9 times

View full text PDF listing >>



Advertisement

Disclaimer
1.1532 s